Erythropoietin with Iron Supplementation to Prevent Allogeneic Blood Transfusion in Total Hip Joint Arthroplasty. A Randomized, Controlled Trial
Overview
Affiliations
Background: The optimum regimen of epoetin alfa for prevention of allogeneic blood transfusion is unknown.
Objective: To determine whether a modified regimen of epoetin alfa reduces allogeneic blood transfusion in patients undergoing hip arthroplasty.
Design: Randomized, double-blind, multicenter trial comparing two modified dose regimens of epoetin alfa with placebo.
Setting: 13 teaching hospitals and 4 community hospitals in Canada.
Patients: 201 patients undergoing primary hip arthroplasty who had a hemoglobin concentration of 98 to 137 g/L and did not predonate blood.
Intervention: Patients were assigned in a 3:5:5 ratio to receive four weekly doses of epoetin alfa, 40 000 U (high-dose; n = 44) or 20 000 U (low-dose; n = 79), or placebo (n = 78), starting 4 weeks before surgery. All patients received oral iron supplementation, 450 mg/d, for 42 or more days before surgery.
Measurements: The primary end point was allogeneic transfusion. Secondary end points were thromboembolic events and change in reticulocyte count and hemoglobin concentration.
Results: Both modified epoetin alfa regimens significantly reduced the need for allogeneic transfusion: Five (11.4%) patients in the high-dose group (P = 0.001) and 18 (22. 8%) patients in the low-dose group (P = 0.003) had transfusion, compared with 35 (44.9%) patients in the placebo group. The hematologic response was substantial in patients who received epoetin alfa. In the high-dose group, low-dose group, and placebo group, the preoperative increase in reticulocyte count was 58.8, 37. 0 and 1.8 x 10(9) cells/L (P < 0.001), respectively, and the increase in hemoglobin concentration was 19.5, 17.2, and 1.2 g/L (P < 0.001). The incidence of thromboembolic events did not differ among groups.
Conclusions: Both modified epoetin alfa regimens were effective compared with placebo in reducing allogeneic transfusion in patients undergoing hip arthroplasty. Patients who received high-dose epoetin alfa had the lowest transfusion rate.
Blood management protocol for baseline anemic patients undergoing hip arthroplasty.
Hourlier H, Fricault G, Fennema P Arch Orthop Trauma Surg. 2025; 145(1):143.
PMID: 39853461 DOI: 10.1007/s00402-025-05764-5.
Hourlier H, Fennema P J Orthop Surg Res. 2023; 18(1):918.
PMID: 38041115 PMC: 10693030. DOI: 10.1186/s13018-023-04404-1.
Patient Blood Management, Anemia, and Transfusion Optimization Across Surgical Specialties.
Kiyatkin M, Mladinov D, Jarzebowski M, Warner M Anesthesiol Clin. 2023; 41(1):161-174.
PMID: 36871997 PMC: 10066799. DOI: 10.1016/j.anclin.2022.10.003.
Zhao H, Meng J, Sun T, Wan Z, Qin S, Zhang F J Orthop Surg Res. 2022; 17(1):542.
PMID: 36522748 PMC: 9753310. DOI: 10.1186/s13018-022-03436-3.
Greenberg J, Zwiep T, Sadek J, Malcolm J, Mullen K, McIsaac D Can J Surg. 2021; 64(5):E491-E509.
PMID: 34598927 PMC: 8526150. DOI: 10.1503/cjs.011519.